slotkoers
Korea S.E.
00:00:00 30-04-2024
|
Variatie 5 dagen
|
Verschil t.o.v. 1 jan (%)
|
14.790
KRW
|
+3,14%
|
|
+7,10%
|
-8,36%
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Marktkapitalisatie
1 |
143.216
|
199.288
|
286.048
|
170.481
|
147.076
|
Bedrijfswaarde
1 |
112.869
|
195.779
|
229.858
|
150.124
|
91.514
|
K/w-verhouding
|
-28,5
x
|
-22,6
x
|
-10,7
x
|
-4,88
x
|
-4,99
x
|
Dividendrendement
|
-
|
-
|
-
|
-
|
-
|
Marktkapitalisatie/omzet
|
29,9
x
|
37,5
x
|
65,6
x
|
41,8
x
|
26,4
x
|
Bedrijfswaarde/omzet
|
23,6
x
|
36,9
x
|
52,7
x
|
36,8
x
|
16,4
x
|
Bedrijfswaarde/EBITDA
|
-29,8
x
|
-26,2
x
|
-26,9
x
|
-5,12
x
|
-3,4
x
|
Bedrijfswaarde/FCF
|
-66,3
x
|
-11,1
x
|
-34,3
x
|
-8,7
x
|
-2,84
x
|
FCF Yield
|
-1,51%
|
-8,97%
|
-2,92%
|
-11,5%
|
-35,2%
|
Price to Book
|
4,64
x
|
5,78
x
|
3,26
x
|
3,43
x
|
2,06
x
|
Aantal aandelen (in duizenden)
|
3.809
|
3.892
|
5.874
|
5.879
|
9.113
|
Referentieprijs
2 |
37.600
|
51.200
|
48.700
|
29.000
|
16.140
|
Datum van publicatie
|
13/03/20
|
19/03/21
|
21/03/22
|
20/03/23
|
19/03/24
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Omzet
1 |
4.783
|
5.312
|
4.363
|
4.075
|
5.575
|
EBITDA
1 |
-3.788
|
-7.462
|
-8.546
|
-29.333
|
-26.911
|
Bedrijfsresultaat (EBIT)
1 |
-4.519
|
-8.513
|
-10.108
|
-33.233
|
-32.057
|
Operationele Marge
|
-94,47%
|
-160,28%
|
-231,68%
|
-815,61%
|
-575%
|
Resultaat voor belastingen (EBT)
1 |
-4.346
|
-8.763
|
-19.272
|
-34.913
|
-22.913
|
Nettowinst (verlies)
1 |
-4.346
|
-8.763
|
-19.272
|
-34.913
|
-22.913
|
Nettomarge
|
-90,85%
|
-164,97%
|
-441,72%
|
-856,84%
|
-410,99%
|
WPA
2 |
-1.317
|
-2.270
|
-4.533
|
-5.940
|
-3.235
|
Free Cash Flow
1 |
-1.702
|
-17.565
|
-6.708
|
-17.249
|
-32.209
|
FCF-marge
|
-35,58%
|
-330,69%
|
-153,75%
|
-423,33%
|
-577,74%
|
Kasstroomconversie (ebitda)
|
-
|
-
|
-
|
-
|
-
|
Kasstroomconversie (nettowinst)
|
-
|
-
|
-
|
-
|
-
|
Dividend per aandeel
|
-
|
-
|
-
|
-
|
-
|
Datum van publicatie
|
13/03/20
|
19/03/21
|
21/03/22
|
20/03/23
|
19/03/24
|
Fiscaal tijdperk: december |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Nettoschuldpositie
1 |
-
|
-
|
-
|
-
|
-
|
Nettokaspositie
1 |
30.348
|
3.509
|
56.190
|
20.357
|
55.562
|
Hefboom (schuld/ebitda)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.702
|
-17.565
|
-6.708
|
-17.249
|
-32.209
|
ROE (netto-inkomsten/eigen vermogen)
|
-20,9%
|
-26,8%
|
-31,5%
|
-50,8%
|
-37,8%
|
ROA (netto-inkomsten/totale activa)
|
-12,1%
|
-9,94%
|
-6,66%
|
-20%
|
-22%
|
Totale activa
1 |
35.833
|
88.193
|
289.379
|
174.599
|
104.366
|
Nettoactief per aandeel
2 |
8.101
|
8.859
|
14.957
|
8.447
|
7.830
|
Cashflow per aandeel
2 |
1.406
|
3.406
|
10.566
|
8.390
|
7.019
|
Capex
1 |
427
|
12.018
|
953
|
4.145
|
4.924
|
Capex/omzet
|
8,93%
|
226,27%
|
21,83%
|
101,72%
|
88,32%
|
Datum van publicatie
|
13/03/20
|
19/03/21
|
21/03/22
|
20/03/23
|
19/03/24
|
|
Vaira. 1 jan.
|
Kapi.
|
---|
| -8,36% | 94,99 mln. | | +0,63% | 42,86 mld. | | +12,14% | 42,74 mld. | | +44,30% | 41,36 mld. | | -6,20% | 27,68 mld. | | +5,90% | 25,15 mld. | | -23,64% | 18,63 mld. | | +28,35% | 12,37 mld. | | -3,42% | 11,92 mld. | | +7,04% | 11,21 mld. |
Biotechnologie & Medisch Onderzoek - Andere
|